BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17063617)

  • 1. Dendritic cells: emerging roles in tumor immunotherapy.
    Buchsel PC; DeMeyer ES
    Clin J Oncol Nurs; 2006 Oct; 10(5):629-40. PubMed ID: 17063617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation.
    Avigan D; Wu Z; Gong J; Joyce R; Levine J; Elias A; Richardson P; Milano J; Kennedy L; Anderson K; Kufe D
    Clin Cancer Res; 1999 Oct; 5(10):2735-41. PubMed ID: 10537336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte-macrophage-colony-stimulating factor and other cytokines: as adjuncts to cancer immunotherapy, stem cell transplantation, and vaccines.
    Arellano M; K Waller E
    Curr Hematol Rep; 2004 Nov; 3(6):424-31. PubMed ID: 15496276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
    Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy.
    Ueda Y; Itoh T; Fuji N; Harada S; Fujiki H; Shimizu K; Shiozaki A; Iwamoto A; Shimizu T; Mazda O; Kimura T; Sonoda Y; Taniwaki M; Yamagishi H
    Cancer Immunol Immunother; 2007 Mar; 56(3):381-9. PubMed ID: 16830156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dendritic cell-based cancer immunotherapies.
    Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
    Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Matsuura I; Noguchi K; Yamaue H
    Clin Cancer Res; 2002 Aug; 8(8):2742-9. PubMed ID: 12171908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.
    Nasi ML; Lieberman P; Busam KJ; Prieto V; Panageas KS; Lewis JJ; Houghton AN; Chapman PB
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):139-44. PubMed ID: 10641571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of sargramostim (rhGM-CSF) as immunotherapy.
    Waller EK
    Oncologist; 2007; 12 Suppl 2():22-6. PubMed ID: 18039636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
    Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte macrophage colony-stimulating factor: current practice and novel approaches.
    Buchsel PC; Forgey A; Grape FB; Hamann SS
    Clin J Oncol Nurs; 2002; 6(4):198-205. PubMed ID: 12087615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dendritic cells present particulate E7 protein of human papillomavirus and induce strong immunity].
    Li J; Gao HQ; Zhao CL; Li LZ; Ji CY; Hou M; Plebaski M
    Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):932-6. PubMed ID: 15329282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells: limited potential in immunotherapy.
    Soruri A; Zwirner J
    Int J Biochem Cell Biol; 2005 Feb; 37(2):241-5. PubMed ID: 15474968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
    Jinushi M; Hodi FS; Dranoff G
    Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy.
    Siena S; Di Nicola M; Bregni M; Mortarini R; Anichini A; Lombardi L; Ravagnani F; Parmiani G; Gianni AM
    Exp Hematol; 1995 Dec; 23(14):1463-71. PubMed ID: 8542932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.
    Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H
    Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.